Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)

This is a randomized open-label multicentre Phase III superiority study of the effect of adding SBRT to the standard of care treatment on overall survival in patients with rare oligometastatic cancers. Patients will be randomized in a 1:1 ratio between current standard of care treatment vs. standard of care treatment + SBRT to all sites of known metastatic disease. The primary objective of this trial is to assess if the addition of stereotactic body radiotherapy (SBRT) to standard of care treatment improves overall survival (OS) as compared to standard of care treatment alone in patients wit

Trial Details

NCT ID
NCT04498767
Phase
NA
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Stereotactic body radiotherapy
  • Palliative RT
Locations (sample)
  • Anderlecht, Belgium|50.83619,4.31454
  • Ghent, Belgium|51.05,3.71667
  • Wilrijk, Belgium|51.16734,4.39513
  • Lille, France|50.63391,3.05512
  • Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

  • Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
  • Controlled primary tumour, defined as:
  • at least 3 months since original tumour treated definitively, with no progression at primary site
  • Total number of oligometastases of 1-5 including:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →